Evidence map›Paper›PMID 40836992›Full record

ArticleFrontiers in drug delivery2024

Choice of adjuvant and antigen composition alters the immunogenic profile of a SARS-CoV-2 subunit vaccine.

William R Lykins, Jeroen Pollet, Jessica A White, Brian Keegan, Leroy Versteeg, Ulrich Strych, Wen-Hsiang Chen, Raodoh Mohamath, Gabi Ramer-Denisoff, Sierra Reed and 10 more

Abstract read
In one paragraph

Article in Frontiers in drug delivery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

William R LykinsAccess to Advanced Health Institute, Seattle, WA, United States.
Jeroen PolletTexas Children's Hospital Center for Vaccine Development, Houston, TX, United States.
Jessica A WhitePATH, Seattle, WA, United States.
Brian KeeganTexas Children's Hospital Center for Vaccine Development, Houston, TX, United States.
Leroy VersteegTexas Children's Hospital Center for Vaccine Development, Houston, TX, United States.
Ulrich StrychTexas Children's Hospital Center for Vaccine Development, Houston, TX, United States.
Wen-Hsiang ChenTexas Children's Hospital Center for Vaccine Development, Houston, TX, United States.
Raodoh MohamathAccess to Advanced Health Institute, Seattle, WA, United States.
Gabi Ramer-DenisoffAccess to Advanced Health Institute, Seattle, WA, United States.
Sierra ReedAccess to Advanced Health Institute, Seattle, WA, United States.
Samuel BeaverAccess to Advanced Health Institute, Seattle, WA, United States.
Alana GerhardtAccess to Advanced Health Institute, Seattle, WA, United States.
Emily A VoigtAccess to Advanced Health Institute, Seattle, WA, United States.
Mark A Tomai3M Health Care, St. Paul, MN, United States.
Robert SitrinPATH, Seattle, WA, United States.
Robert K M ChoyPATH, Seattle, WA, United States.
Frederick J CasselsPATH, Seattle, WA, United States.
Peter J HotezTexas Children's Hospital Center for Vaccine Development, Houston, TX, United States.
Maria Elena BottazziTexas Children's Hospital Center for Vaccine Development, Houston, TX, United States.
Christopher B FoxAccess to Advanced Health Institute, Seattle, WA, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

adjuvant formulationbivalent vaccinereceptor binding domainSARS-CoV-2toll-like receptorvaccine development

Identifiers

PMID40836992
PMCPMC12363249

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.